Company: SUPN
Filing Date: 2025-06-16
Form Type: SC TO-C
Source: 0001104659-25-059761
Chunk: 6

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-06-16
Form: SC TO-C
Chunk 6
---
 Company and Purchaser in connection with the Merger Agreement.
Moreover, certain representations and warranties in the Merger Agreement may be subject to a contractual standard of materiality different
from what might be viewed as material to stockholders or investors or may have been used for the purpose of allocating risk between the
parties to the Merger Agreement instead of establishing these matters as facts. Accordingly, investors should consider the information
in the Merger Agreement in conjunction with the entirety of the factual disclosure about the Company and Sage in the Company’s and
Sage’s respective public reports filed with the Securities and Exchange Commission (the “SEC”). Information concerning
the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information
may or may not be fully reflected in the Company’s or Sage’s public disclosures.

<div align='center'>3</div>

| Item 8.01 | Other Events. |

On June 16, 2025, the Company
issued a joint press release with Sage announcing the execution of the Merger Agreement and held an investor conference call. A copy of
the joint press release is filed as Exhibit 99.1 hereto, and the text of such joint press release is incorporated herein by reference.
A copy of the investor presentation presented on the conference call is filed as Exhibit 99.2 hereto and posted on the Company’s
website, and the text of such investor presentation is incorporated herein by reference.

Additional Information about the Tender Offer and Where to Find It

The tender offer for the outstanding common stock ofSage Therapeutics, Inc. (“Sage”) has not been commenced. This filing
does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell Sage securities. At the time the tender
offer is commenced, Supernus Pharmaceuticals, Inc. (“Supernus”) and Saphire Inc., a direct wholly owned subsidiary of Supernus
(“Purchaser”), will file a Tender Offer Statement on Schedule TO (including an Offer to Purchase) with the Securities and
Exchange Commission (the “SEC”) and thereafter, Sage will file a Solicitation/Recommendation Statement on Schedule 14D-9 with
the SEC, in each case, with respect to the tender offer. The solicitation and offer by Supernus to purchase shares of Sage common stock
will only be made pursuant to such Offer to Purchase and related materials. Once filed, investors and security holders are urged to read
these materials